Questions & explanations
1. Compare primary (idiopathic) membranous nephropathy with secondary membranous nephropathy. What is a common cause of secondary disease?
Primary membranous nephropathy has no known cause, and most cases are linked to anti-PLA2R antibodies. Secondary membranous nephropathy is caused by another disease, such as lupus, hepatitis B, cancer, or certain drugs. For example, hepatitis B infection can trigger immune complexes that deposit in the kidney, leading to membranous nephropathy. In secondary cases, anti-PLA2R antibodies are usually absent. Treatment of secondary disease focuses on the underlying cause, like antiviral drugs for hepatitis B. Removing the cause often improves the kidney disease. So, it is important to check for secondary causes before starting immunosuppression.
2. Can Alport syndrome be inherited in different patterns? Explain the difference in severity between males and females in X-linked Alport syndrome.
Yes, Alport syndrome can be X-linked (most common), autosomal recessive, or autosomal dominant. In X-linked Alport, the mutated gene is on the X chromosome. Males have only one X chromosome, so they are severely affected and often develop kidney failure by age 20-30. Females have two X chromosomes; if one is mutated, they usually have milder symptoms like blood in urine but rarely develop kidney failure. However, some females can have significant disease due to skewed X-inactivation. In autosomal recessive Alport, both parents must carry a mutation, and both males and females are equally severe. Autosomal dominant Alport is rare and milder.
3. How does thin basement membrane nephropathy (TBMN) differ from Alport syndrome in terms of kidney outcome?
Thin basement membrane nephropathy (TBMN) is a much milder condition. It is also caused by mutations in COL4A3 or COL4A4, but usually only one copy is affected (autosomal dominant). Patients typically have blood in urine from childhood but rarely develop kidney failure. Kidney function stays normal for life, and protein in urine is usually low. In contrast, Alport syndrome often leads to progressive kidney failure, especially in males with X-linked disease. Hearing loss and eye problems are common in Alport but absent in TBMN. A kidney biopsy can help tell them apart by measuring the thickness of the glomerular basement membrane.
4. What is the Gibbs-Donnan effect in the context of dialysis?
The Gibbs-Donnan effect describes how charged particles (ions) distribute unevenly across a membrane when there are large, trapped charged molecules (like proteins) on one side. In dialysis, this effect causes small ions (like sodium and chloride) to move differently than expected. For example, negatively charged proteins in the blood attract positive ions (like sodium) and repel negative ions (like chloride). This leads to a small difference in ion concentrations between blood and dialysate. The effect is important for calculating the correct dialysate composition to keep the patient's electrolyte balance stable.
5. Compare the challenges of implementing 0by25 in a wealthy country versus a poor country.
In a wealthy country, the main challenge is raising awareness among doctors and patients, and integrating new guidelines into existing systems. Resources like dialysis machines and labs are already available. In a poor country, the challenges are much bigger: lack of clean water, electricity, trained staff, and basic medicines. Dialysis may be unavailable or unaffordable. The initiative must focus on simple, low-tech solutions like early detection with urine dipsticks and treating infections. Wealthy countries can help by funding and providing expertise. Both settings need political will and community engagement.
6. A patient with lupus nephritis achieves complete remission after treatment. What does 'complete remission' mean, and why is it important?
Complete remission means the patient has normal or near-normal kidney function, no active urine sediment (no blood or casts), and protein in urine has dropped to less than 0.5 grams per day. It shows that the treatment has stopped the kidney inflammation. Achieving complete remission is important because it greatly reduces the risk of kidney failure in the long term. Patients who reach remission have a much better chance of keeping their kidney function for many years. Those who do not achieve remission are more likely to progress to end-stage kidney disease. So, doctors aim for complete remission with treatment.
7. What is membranoproliferative glomerulonephritis (MPGN)?
MPGN is a kidney disease where the glomeruli (tiny filters in the kidney) become inflamed and thickened. It is called membranoproliferative because the glomerular basement membrane (the filter's wall) thickens and cells multiply. There are two main types: type I has immune deposits (clumps of proteins) under the endothelium (inner lining), and type III has deposits in the membrane. C3 glomerulopathy is a related disease where only C3 protein (a complement protein) deposits without immunoglobulins (antibodies). MPGN often presents with blood and protein in urine, high blood pressure, and kidney function decline.
8. A patient with Alport syndrome has mild protein in urine and normal kidney function. What management can slow the loss of kidney function?
The main treatment is to use angiotensin-converting enzyme inhibitors (ACE inhibitors) or angiotensin receptor blockers (ARBs). These drugs lower blood pressure and reduce protein in urine, which protects the kidneys. They are started even if blood pressure is normal, as long as there is protein in urine. Avoiding nephrotoxic drugs like NSAIDs (pain relievers) is also important. Regular monitoring of kidney function, blood pressure, and protein in urine is needed. There is no cure, but these measures can delay kidney failure by many years. In advanced stages, dialysis or kidney transplant may be needed.
9. Compare the management of class V lupus nephritis with class III/IV.
Class V (membranous) LN mainly causes protein in urine without much active inflammation. Treatment often includes angiotensin-converting enzyme inhibitors (ACEi, drugs that lower blood pressure and reduce protein leak) and sometimes immunosuppressants like calcineurin inhibitors (e.g., tacrolimus) or rituximab (a biologic drug that targets B cells). In contrast, class III/IV LN has active inflammation and requires more aggressive immunosuppression with high-dose steroids and MMF or cyclophosphamide. The goal for class V is to reduce proteinuria, while for class III/IV it is to stop active inflammation.
10. What other systemic diseases besides SLE can cause glomerulonephritis? Give one example and how it affects the kidney.
One example is vasculitis, such as granulomatosis with polyangiitis (GPA). In GPA, the immune system attacks small blood vessels, including those in the kidney. This causes a type of glomerulonephritis called pauci-immune crescentic GN, where there are few immune deposits but many crescents (scar-like structures) in the glomeruli. Patients often have blood in urine, protein in urine, and rapid loss of kidney function. Other systemic diseases include Goodpasture syndrome (anti-GBM disease) and Henoch-Schönlein purpura (IgA vasculitis). Each has a different immune pattern and requires specific treatment.
11. How does measuring anti-PLA2R antibody levels help in managing membranous nephropathy? Give an example.
Anti-PLA2R antibody levels reflect disease activity. High levels usually mean active disease with heavy protein in urine. Falling levels after treatment suggest a good response. For example, if a patient starts rituximab and the antibody level drops by 90% after 6 months, protein in urine often decreases later. If the level stays high, the treatment may not be working, and the doctor might switch to another drug. Also, rising antibody levels can predict a relapse before protein in urine increases. So, regular antibody tests help guide treatment decisions without waiting for kidney function to worsen.
12. Compare the benefits and challenges of using telemedicine for AKI care in rural versus urban settings.
In rural areas, telemedicine provides access to kidney specialists that are otherwise unavailable, which can save lives. It reduces travel time and costs for patients. In urban areas, telemedicine can offer convenience and reduce hospital overcrowding by allowing remote monitoring. However, challenges include internet connectivity issues in rural regions and the need for training staff to use the technology. Also, telemedicine cannot replace hands-on procedures like inserting dialysis catheters. Both settings benefit from faster specialist input, but rural areas gain the most in terms of access.